Head-to-head evidence
BR1017 vs Candesartan/Rosuvastatin/Ezetimibe
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: AT1 receptor; NPC1L1; HMG-CoA reductase · full Atherosclerotic Cardiovascular Disease pipeline
BR1017
Developed by Boryung Pharmaceutical
NCT05930028 · Phase 3 · completed
The study was randomized and double-blind, included 148 participants, and used active comparator groups receiving fimasartan or ezetimibe/atorvastatin. Its primary measures were changes in systolic blood pressure and LDL cholesterol, and because no primary-endpoint results are available, it cannot establish whether the treatment was effective.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Candesartan/Rosuvastatin/Ezetimibe
Developed by Hyundai Pharm
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BR1017's landscape · Candesartan/Rosuvastatin/Ezetimibe's landscape